5-HT7 Receptor Antagonists as a New Class of Antidepressants
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
It is now admitted that major depression is associated with monoaminergic dysfunctions as well as with functional brain plasticity impairments. Despite the wide variety of medications available to treat such a syndrome, two foremost problems still remain unresolved: one-third of patients do not respond to any treatment and there is an unwanted 2-4 week delay in the onset of therapeutic action of all available antidepressant drugs. These issues draw attention to the need and urgency to develop more efficacious treatments and to accelerate the antidepressant response. The combination of an atypical antipsychotic, known to be a potent 5-HT(7) receptor antagonist, with an antidepressant has been recently proposed as an alternative therapy. Hence, blockade of 5-HT(7) receptors might represent a key determinant for this hastening strategy. This review summarizes recent data that put emphasis on the putative antidepressant properties of selective 5-HT(7) receptor antagonists. The use of such ligands seems very promising to elaborate novel generations of antidepressants that surpass the efficacy and onset of action limitations of existing antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Hippocampal cell proliferation regulation by repeated stress and antidepressants
Chen, H., Pandey, G. N., & Dwivedi, Y. (2006) · NeuroReport · doi:10.1097/01.wnr.0000221827.03222.70 · Cited by 115
Cited by
Serotonin Receptors – From Molecular Biology to Clinical Applications
PYTLIAK, M., VARGOVÁ, V., MECHÍROVÁ, V., & FELŠÖCI, M. (2011) · Physiological Research · doi:10.33549/physiolres.931903 · Cited by 318
Leopoldo, M., Lacivita, E., Berardi, F., Perrone, R., & Hedlund, P. B. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.013 · Cited by 198
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Andreetta, F., Carboni, L., Grafton, G., Jeggo, R., Whyment, A. D., van den Top, M., Hoyer, D., Spanswick, D., & Barnes, N. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13432 · Cited by 28
“, 2013) and is the focus of various projects to identify novel therapeutics to treat conditions such as depression, sleep disorders and cognitive deficits (Mnie-Filali et al., 2007).”
Background
Metadata
- Venue
- Drug News & Perspectives
- Publisher
- Portico
- Published
- 2007
- Volume
- 20
- Issue
- 10
- Pages
- 613
- ISSN
- 0214-0934 (ISSN-L)
- 2013-0139
- OpenAlex
- W2058651616
- Cited by
- 68
- References
- 3
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 5-HT7 Receptor Antagonists as a New Class of Antidepressants. https://app.cochat.ai/papers/10.1358/dnp.2007.20.10.1181354
- The paper
- 5-HT7 Receptor Antagonists as a New Class of Antidepressants. (2007). Drug News & Perspectives. https://doi.org/10.1358/dnp.2007.20.10.1181354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.